DRKS00029906招募中Unknown

utritional study on the importance of a probiotic multispecies product for the composition and diversity of the intestinal microbiome with simultaneous administration of antibiotics - OMNi-BiOTiC® 10

Institut AllergoSanPharmazeutische Produkte Forschungs- und Vertriebs GmbH0 个研究点目标入组 500 人开始时间: 2023年3月20日最近更新: 2024年8月19日

试验速览

暂无简介。

•According to medical assessment, necessary antibiotic therapy of a bacterial infectious disease (e.g. bronchopulmonary infections, urinary tract infections) by broad-spectrum antibiotics administered orally or intravenously (e.g. clindamycin, Cephalosporins, fluoroquinolones, macrolides, penicillins)
•The possibility of using antibiotics within 24 hours with the consumption of Study medication to begin
•Written consent after comprehensive information
•No fundamental changes in dietary patterns during the Participation in studies

•Antibiotic use within the last 4 weeks before the start of the study
•Planned intestinal lavage (e.g. before colonoscopy)
•Diarrhoeal disease within the last 4 weeks before the start of studies
•Consumption of other probiotics within the last 4 weeks
•Regular use of laxatives
•Consumption of peristaltic inhibitors
•Chronic diarrhoeal disease (e.g. chronic inflammatory bowel disease or Malassimilation)
•Immunosuppression due to illness and/or medication
•Patients with sepsis, current cancer or dialysis
•Accompanying circumstances that lead to a consistent implementation of probiotics intake and the
•Do not allow keeping a diary (e.g. dementia, ventilation, planned surgery)

发起方

Institut AllergoSanPharmazeutische Produkte Forschungs- und Vertriebs GmbH